News Pipeline Raises $80M to Pursue Potential Myelin Restoring Therapy Pipeline Raises $80M to Pursue Potential Myelin Restoring Therapy by Forest Ray PhD | February 15, 2021 Share this article: Share article via email Copy article link Pipeline TherapeuticsĀ announced that it has raised $80 million in investor financing to develop neuroregenerative therapies for neurological disorders, including those like multiple sclerosis (MS) that are marked by the loss of myelin. The money will support the research and development ofĀ several candidate therapies, with three aimed at promoting and restoring neuronal health. āWe are proud to have this significant support for our mission of developing first- and best-in-class neuroregenerative product candidates for unserved and underserved neurological indications,” Carmine Stengone, president and CEO of Pipeline, said in a press release. The lead treatment candidate for MS is called PIPE-307, and is designed to help regrow myelin (remyelination), the protective sheath that insulates nerve cell axons against signal loss, much like the coating found around electrical wires. Pipeline Therapeutics recently launched a Phase 1 clinical trial (NCT04725175) to assess the safety and tolerability of PIPE-307 in up to 72 healthy volunteers, ages 18 to 55, in Australia. Contact information for this trial, which is not yet recruiting, can be found here. The study is separated into three parts. Part 1 consists of a single ascending dose (SAD) study, involving about 48 volunteers over six weeks. Part 2 consists of a multiple ascending dose (MAD) study in approximately 24 people over seven weeks. In part 3, roughly eight individuals from the SAD study will take PIPE-307 with a meal to evaluate how food might affect the medication’s bioavailability. Part 3 will run for six weeks. Although remyelination occurs spontaneously in MS lesions, disease progression increasingly wears on this process to the point that it eventually fails. As myelin is lost, nerve signals traveling from the brain to distant parts of the body are disrupted, and nerve damage and chronic disability occur. No available therapy can restore myelin, making this one of the greatest unmet needs for people with MS. PIPE-307 is a muscarinic receptor type 1 (M1) antagonist, meaning that it inactivates the M1 receptor. Blocking muscarinic receptors has the effect of stimulating oligodendrocyte progenitor cells to grow into mature, myelin-producing oligodendrocyte cells. Other muscarinic receptors have been evaluated as potential therapeutic targets for MS. To date, a lack of knowledge concerning exactly which receptor subtypes are most involved in MS has slowed their path to clinical use. Other candidate therapies for neurological disorders in Pipeline’s portfolio include compounds targeting remyelination and neuroinflammation, axonal repair, and sensorineural hearing loss. Pipeline’s Series C financing round was “oversubscribed,” the company reported in its release. āWe are delighted to welcome the new investors in our Series C round, and are grateful to our existing shareholders for their continued support,ā Stengone said. āWe are proud to have this significant support for our mission of developing first- and best-in-class neuroregenerative product candidates for unserved and underserved neurological indications.ā Print This Page About the Author Forest Ray PhD Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California. Tags neurological disorders, Pipeline Therapeutics, remyelination
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk